Boehringer Ingelheim, a major German pharmaceutical company, has entered into an agreement with China’s Peking University Health Science Center (PKUHSC) to establish a joint laboratory for human use drug research. This long-term partnership builds upon an initial teaching and scientific research cooperation memorandum of understanding signed back in 2014.
Since the initial agreement, Boehringer Ingelheim has provided annual internship opportunities for doctoral students in medical epidemiology at Peking University, with placements both in China and abroad. The collaboration has encompassed research into skin diseases and sudden infectious diseases, including the treatment of pustular psoriasis (GPP) with spesolimab. The new joint laboratory will concentrate its efforts on inflammatory immunity, oncology, cardio-renal metabolism, ophthalmology, and emerging treatment fields, as well as strengthening talent development initiatives.- Flcube.com
